Update results from ALTER-C-001: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC-A single-arm, multicenter, phase II clinical trial.
第一作者机构：[1]UESTC, Sichuan Canc Hosp & Inst, Affiliated Canc Hosp, Dept Gastrointestinal Surg,Sch Med, Chengdu, Peoples R China[2]Southwest Med Univ, Dept Med Oncol, Affiliated Hosp, Luzhou, Peoples R China[3]Chongqing Univ, Gorges Hosp 3, Dept Med Oncol, Chongqing, Peoples R China[4]UESTC, Sichuan Canc Hosp & Inst, Affiliated Canc Hosp, Dept Med Oncol,Sch Med, Chengdu, Peoples R China[5]Chongqing Univ, Canc Hosp, Gastrointestinal Canc Ctr, Chongqing, Peoples R China
推荐引用方式(GB/T 7714)：
Yan Jin,Han Yunwei,Zhang Li,et al.Update results from ALTER-C-001: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC-A single-arm, multicenter, phase II clinical trial.[J].JOURNAL OF CLINICAL ONCOLOGY.2021,39(15):doi:10.1200/JCO.2021.39.15_suppl.e15550.
APA：
Yan, Jin,Han, Yunwei,Zhang, Li,Jin, Yongdong&Sun, Hao.(2021).Update results from ALTER-C-001: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC-A single-arm, multicenter, phase II clinical trial..JOURNAL OF CLINICAL ONCOLOGY,39,(15)
MLA：
Yan, Jin,et al."Update results from ALTER-C-001: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC-A single-arm, multicenter, phase II clinical trial.".JOURNAL OF CLINICAL ONCOLOGY 39..15(2021)
医学